Registration Dossier

Administrative data

Description of key information

There are several case reports available in literature. However, these reported cases mainly refer to acute poisoning with the formulated products, not with the active ingredient (GA) itself. In poisonings with products containing Glufosinate ammonium the surfactants in the formulation, as well as the other ingredients, may play an important role for some of the symptoms observed. 

The main findings of these reports are summarized as follows: 

Human poisoning cases resulted in nausea, vomiting, diarrhea, abdominal pain, tremor, hypotension, bradycardia or tachycardia, muscle weakness, drowsiness, loss of consciousness and coma, convulsions, and respiratory arrest. Rarely hyperthermia has been described, as has in one case of ingestion of a very high dose diabetes insipidus, and in one case double vision and nystagmus due to palsy of the 6th cranial nerve. Retro- and anterograde amnesia and memory deficits can occur. The fatality rate in reported poisonings is about 18%. The neurological symptoms may suddenly appear with a delay (latency period) of 8 to 48 hours

without warning. Both cytotoxic and vasogenic edema have been reported in brain regions.

Additional information

Based on the effects on the human central nervous system reported after single exposures to GA formulations and based on the fact that these effects have also been reported in animals exposed to the pure substance, glufosinate ammonium is classified for target organ toxicity (central nervous system) in accordance with Regulation (EC) 1272/2008 (STOT SE Cat.1; H370).